ABVC BioPharma, Inc. (ABVC) stock
ABVCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ECOC
$0.96−0.03 (-3.03%)
Close on Nov 12, 2026Market cap $25.59MP/E –Yield –
ABVC BioPharma operating margin
Operating margin is operating income as a percentage of revenue.
ABVC BioPharma's operating margin for the twelve months ending Dec 31, 2024 was -1589.6%. For fiscal 2025 it was -2416.0%, against -1589.6% the year before. The highest annual figure on record is -492.9% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -2416.0% | −826.4 |
| FY2024 | Dec 31, 2024 | -1589.6% | +2849.6 |
| FY2023 | Dec 31, 2023 | -4439.2% | −2880.7 |
| FY2022 | Dec 31, 2022 | -1558.5% | +1731.5 |
| FY2021 | Dec 31, 2021 | -3290.1% | −1529.2 |
| FY2020 | Dec 31, 2020 | -1760.9% | −1268.0 |
| FY2019 | Dec 31, 2019 | -492.9% | +1783.4 |
| FY2013 | Sep 30, 2013 | -2276.3% | +17728.0 |
| FY2012 | Sep 30, 2012 | -20004.3% | +39176.4 |
| FY2011 | Sep 30, 2011 | -59180.7% | −46465.5 |
| FY2010 | Sep 30, 2010 | -12715.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -246.8% | +235293.0 |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -35837.4% | −12196.1 |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -77.7% | +13488.7 |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -734.2% | +35177.4 |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -235539.8% | −234053.8 |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -23641.3% | −23109.4 |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -13566.3% | −4775.4 |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -35911.6% | −35257.4 |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -1486.0% | +22749.0 |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -531.9% | +1458.6 |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -8790.9% | −2316.9 |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -654.2% | −178.2 |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -24235.1% | −16435.8 |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -1990.5% | −874.3 |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -6474.1% | −5947.0 |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -476.1% | +1010.7 |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -7799.3% | −6675.1 |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -1116.2% | −552.0 |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -527.1% | −272.3 |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -1486.8% | −1142.6 |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -1124.2% | −913.7 |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -564.2% | −263.7 |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -254.9% | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -344.2% | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -210.5% | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -300.6% | – |
See a number that looks wrong?